Yahoo · Nov 10, 2026
Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that the first participant has been dosed in BLOOM, the Company's Phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression (PPD). LPCN 1154 is being developed as a 48-hour oral treatment intended for at-home use.

